

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**208341Orig1s000**

**MICROBIOLOGY/VIROLOGY REVIEW(S)**

**DIVISION OF ANTIVIRAL PRODUCTS (HFD-530) VIROLOGY REVIEW**

**NDA: 208341      SDN: 000**

**DATE REVIEWED: 03/17/2015**

**Virology Reviewer: Lisa K. Naeger, Ph.D.**

**NDA#: 208341**

**Serial #: 000**

**Reviewer's Name(s): Lisa K. Naeger, Ph.D.**

**Sponsor's Name and Address:**

Gilead Sciences, Inc  
333 Lakeside Drive  
Foster City, CA 94404

**Initial Submission Dates:**

**Correspondence Date:** October 28, 2015

**CDER Receipt Date:** October 28, 2015

**Assigned Date:** October 29, 2015

**Review Complete Date:** March 29, 2016

**PDUFA Date:** June 28, 2016

**Amendments:**

<b>SDN</b>	<b>Date Submitted</b>	<b>Date Received</b>	<b>Date Assigned</b>
------------	-----------------------	----------------------	----------------------

**Related/Supporting Documents:** IND115670, IND106739, NDA204671

<b>Product Names</b>	<b>Sofosbuvir (GS-7977)</b>	<b>Velpatasvir (GS-5816)</b>
<b>Structures</b>	(b) (4)	
<b>Chemical Names</b>	(S)- Isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino) propanoate	(b) (4)
<b>Molecular formula</b>	C <sub>22</sub> H <sub>29</sub> FN <sub>3</sub> O <sub>9</sub> P	C <sub>49</sub> H <sub>54</sub> N <sub>8</sub> O <sub>8</sub>
<b>Molecular weight</b>	529.46	883.00

**Drug category:** Antiviral

**DIVISION OF ANTIVIRAL PRODUCTS (HFD-530) VIROLOGY REVIEW**

**NDA:** 208341      **SDN:** 000

**DATE REVIEWED:** 03/17/2015

**Virology Reviewer:** Lisa K. Naeger, Ph.D.

**Indication:** Fixed-dose combination of velpatasvir, a hepatitis C virus (HCV) NS5A inhibitor and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor and is indicated for the treatment of chronic hepatitis C (CHC) (b) (4) infection

**Dosage Form/Route of administration:** Oral

**Dispensed: Rx**

**Abbreviations:** BVDV, bovine viral diarrhea virus; BL, baseline; DAA, direct acting antiviral; EC<sub>50</sub>, effective concentration at 50%; FC, fold-change; FDA, Food and Drug Administration; FDC, fixed-dose combination; GT, genotype; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IC<sub>50</sub>, inhibitory concentration at 50%; IFN, recombinant human interferon; LDV, ledipasvir; NGS, next generation sequencing; NRTIs, nucleoside reverse transcriptase inhibitors; PBL, peripheral blood lymphocytes; PDVF, protocol defined virologic failure; PI, NS3/4A protease inhibitor; P/R, pegylated interferon/ribavirin; RBV, ribavirin; RSV, respiratory syncytial virus; SDM, site-directed mutants; SOF, sofosbuvir; SVR, sustained virologic response; SVR12, sustained virologic response at 12 week after end of treatment; VEL, velpatasvir; WT, wild-type

**TABLE OF CONTENTS**

*Executive Summary*.....Page 3

**1**    *Recommendations*

**1.1**    *Recommendations on Approvability*.....Page 8

**1.2**    *Recommendation on Phase 4 Commitments*.....Page 8

**2**    *Summary of Virology Assessments*

**2.1**    *Non-Clinical Virology*.....Page9

**2.2**    *Clinical Virology* .....Page 10

**3**    *Administrative signatures*.....Page 13

**4**    *Virology Review*

**4.1**    *Important Milestones in Development*.....Page 14

**4.2**    *Methodology*.....Page 14

**4.3**    *Prior FDA Reviews*.....Page 15

**4.4**    *State of antivirals used for the indication*.....Page 15

**4.5**    *Non-Clinical Virology* .....Page17

**4.6**    *Clinical Studies*.....Page 43

**4.7**    *Clinical Virology*.....Page 47

**5**    *Conclusion*.....Page 66

**6**    *Package Insert*

**6.1**    *Applicant-Proposed*.....Page 68

**6.2**    *FDA-Proposed* .....Page 73

**DIVISION OF ANTIVIRAL PRODUCTS (HFD-530) VIROLOGY REVIEW**

**NDA:** 208341     **SDN:** 000

**DATE REVIEWED:** 03/17/2015

**Virology Reviewer:** Lisa K. Naeger, Ph.D.

**EXECUTIVE SUMMARY**

This NDA for a fixed-dose combination (FDC) of velpatasvir (VEL) and the approved NS5B nucleotide analog inhibitor sofosbuvir (SOF), seeks an indication with and without ribavirin (RBV) for the treatment of adult patients with chronic HCV infection. From a virology perspective, this application for SOF/VEL is approvable.

SOF/VEL is indicated for the treatment of GT1, 2, 3, 4, 5, and 6 HCV infections. The recommended treatment regimen for patients without cirrhosis and patients with compensated cirrhosis (Child-Pugh A) is 12 weeks of SOF/VEL. The recommended treatment regimen for patients with decompensated cirrhosis (Child-Pugh B and C) is 12 weeks of SOF/VEL + RBV. This virology review supports adding a footnote to the Dosage and Administration Table to consider adding RBV to 12 week SOF/VEL for GT3 subjects with compensated cirrhosis, because relapse rates were higher overall in this population and the consequences of failure with resistance to all NS5A inhibitors and potentially SOF for the cirrhotic population are significant. GT3 subjects with compensated cirrhosis treated with 12 weeks SOF/VEL had a relapse rate of 9% compared to 2% for GT3 subjects without cirrhosis. Importantly, relapse rates were much higher (33%) in GT3 compensated cirrhotic subjects who had baseline NS5A resistance-associated polymorphisms (RAPs). Furthermore, all the GT3 virologic failures with compensated cirrhosis had the Y93H NS5A resistance substitution at failure, which confers high-level resistance to all current NS5A inhibitors and may compromise future treatment options. Thus, it is important to optimize chances of virologic success for this advanced patient population. The data support adding RBV to 12 weeks SOF/VEL to optimize SVR12 rates in GT3 patients with compensated cirrhosis.

Sofosbuvir (SOF) is a uridine nucleotide analog inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is required for viral replication. Specifically, the SOF prodrug is hydrolyzed by cellular esterases to a uridine analog monophosphate that is subsequently converted by cellular kinases to uridine analog triphosphate. The uridine analog is incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. Velpatasvir (VEL) is an inhibitor of the HCV NS5A protein, which is required for viral replication. Resistance selection experiments in cell culture and cross-resistance studies indicate velpatasvir targets NS5A as its mode of action.

SOF and VEL have antiviral activity against HCV genotypes (GT) 1, 2, 3, 4, 5, and 6. The EC<sub>50</sub> values for SOF range from 15 to 264 nM against laboratory replicons and the EC<sub>50</sub> values for VEL range from 0.004 to 0.130 nM. Against clinical isolates, median EC<sub>50</sub> values range from 29 - 102 nM and 0.002 – 0.024 nM for SOF and VEL, respectively.

Velpatasvir was not antagonistic in reducing HCV RNA levels in replicon cells when combined with sofosbuvir or IFN- $\alpha$ , RBV, a HCV NS3/4A protease inhibitor, the HCV NS5A inhibitor, ledipasvir, or HCV NS5B non-nucleoside inhibitors, GS-9190 or GS-9669.

In cell culture, HCV replicons with reduced susceptibility to sofosbuvir were selected in cell culture for genotypes 1b, 2a, 2b, 3a, 4a, 5a, and 6a. Reduced susceptibility to

## DIVISION OF ANTIVIRAL PRODUCTS (HFD-530) VIROLOGY REVIEW

NDA: 208341 SDN: 000

DATE REVIEWED: 03/17/2015

Virology Reviewer: Lisa K. Naeger, Ph.D.

sofosbuvir was associated with the NS5B substitution S282T in all replicon genotypes examined. An M289L substitution developed along with the S282T substitution in genotype 2a, 5 and 6 replicons. Site-directed mutagenesis of the S282T substitution in replicons of genotypes 1 to 6 conferred 2- to 18-fold reduced susceptibility to sofosbuvir. HCV genotype 1a, 1b, 2a, 3a, 4a, 5a, and 6a replicon variants with reduced susceptibility to velpatasvir were also selected in cell culture. Selected viruses developed amino acid substitutions at NS5A resistance-associated positions 24, 28, 30, 31, 32, 58, 92, and 93. Phenotypic analysis of site-directed mutagenesis mutant replicons of the selected NS5A substitutions showed that single and double combinations of L31V and Y93H/N in genotype 1a, the combination of L31V +Y93H in genotype 1b, Y93H/S in genotype 3a, and L31V and P32A/L/Q/R in genotype 6 conferred greater than 100-fold reduction in velpatasvir susceptibility. In the genotype 2a replicon, the single mutants F28S and Y93H showed 91-fold and 46-fold reduced susceptibility to VEL, respectively. The single mutant Y93H conferred 3-fold reduced susceptibility to VEL in genotype 4a replicons. Combinations of these NS5A substitutions often showed greater reductions in susceptibility to velpatasvir than single substitutions alone.

### **Clinical Virology Assessment of ASTRAL Trials**

For the FDA resistance analyses (see also the independent analysis of the next generation sequencing data by Virology Reviewer Eric Donaldson, Ph.D.), subjects who died, experienced an AE while serum HCV RNA was undetectable, or were lost to follow-up in the ASTRAL trials were removed from the analyses. Thus, 3 GT1a subjects in ASTRAL 1 and 16 GT3 subjects in ASTRAL 3 were censored for the FDA resistance analysis. The prevalence of baseline NS5A RAPs (any change at amino acid positions 24, 28, 30, 31, 58, 92 and 93) at a sensitivity threshold of 15% of the viral population was assessed in the ASTRAL trials. Analyses were performed to assess the effect of baseline NS5A RAPs and cirrhosis on relapse rates. In addition, the NS5A resistance-associated substitutions that emerged in virologic failures were examined.

### **ASTRAL 1 and 2**

In the ASTRAL 1 and 2 studies of subjects with GT1, 2, 4, 5, and 6, the prevalence of baseline NS5A RAPs was 18% (38/211) in subjects with GT1a HCV infection and 31% (42/134) in subjects with GT1b HCV infection. The most prevalent NS5A RAPs in GT1a were at positions M28 (5%) and H58 (7%). The most prevalent NS5A RAPs in GT1b were at positions 30 (8%), 31 (7%), 58 (9%) and 93 (10%). The prevalence of baseline NS5A RAPs in subjects with GT2 HCV infection was 60% (233/387). The most prevalent GT2 NS5A RAPs were L31M (51%) and K24R/T/Q (17%). The prevalence of baseline NS5A RAPs in subjects with GT4, GT5, and GT6 infection was 63% (73/115), 9% (3/35), and 83% (35/42), respectively. The predominant polymorphisms were at positions 28, 30 and 58 in GT4 and at positions 24, 28, 30 and 58 in GT6.

There were only 2 GT1 virologic failures in ASTRAL 1 and there were no virologic failures in ASTRAL 2. Thus, for GT2, GT4, GT5 and GT6 subjects, SVR12 rates were 100% with or without the presence of baseline NS5A RAPs. Since there were only 2 GT1 virologic failures, the effect of baseline NS5A polymorphisms was not assessed for GT1 subjects in ASTRAL 1.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.